Spirulina and JAK/STAT Signalling.

JAK Family Kinases: Structure and Activation

The four Janus kinases (JAK1, JAK2, JAK3, TYK2) are non-receptor tyrosine kinases associated with cytokine receptor cytoplasmic domains. Each JAK contains: FERM domain (receptor association); SH2-like domain; pseudokinase domain (JH2; negative regulator; contains the JAK2 Val617Phe MPN mutation site causing constitutive activation in myeloproliferative neoplasms); and kinase domain (JH1). Cytokine binding induces receptor oligomerisation → JAK transphosphorylation on the activation loop (JAK2 Tyr1007/1008; JAK1 Tyr1034/1035; TYK2 Tyr1054/1055) → JAK tyrosine kinase fully active → STAT SH2-binding pTyr docking sites on receptor cytoplasmic tails generated → STAT recruitment. JAK2 is primarily associated with cytokines signalling via homodimeric receptors (EPO-R, THPO-R, GH-R, prolactin-R) and gp130-IL-6-family receptors (with JAK1/TYK2). JAK3 is exclusively associated with the γc (common gamma) chain shared by IL-2/4/7/9/15/21 receptors — loss-of-function JAK3 mutations cause severe combined immunodeficiency (SCID).

STAT Proteins: Phosphorylation, Dimerisation, and Nuclear Translocation

The seven STAT proteins (STAT1–4, STAT5A/B, STAT6) share modular architecture: N-terminal oligomerisation domain; coiled-coil; DBD (DNA-binding domain); linker; SH2 domain (binds receptor pTyr and partner STAT pTyr for dimerisation); transactivation domain (TAD); and C-terminal regulatory Tyr (Tyr705 in STAT3; Tyr701 in STAT1; Tyr694 in STAT5A; Tyr641 in STAT6) that is phosphorylated by JAKs. pTyr-STAT monomers dimerise via reciprocal SH2–pTyr interactions (parallel or anti-parallel dimers) → nuclear translocation via importin-α3/α6 (STAT1 NLS) → GAS elements (5′-TTCN&sub2;-5-GAA-3′; STAT1/3/4/5/6 bind) or ISRE (5′-GAGTTTCNNTTTCC-3′; STAT1-ISGF3 with IRF9 for type I IFN). STAT3 Ser727 is phosphorylated by MAPK/CDK5 in the TAD, providing additional transcriptional activation; STAT3 Lys685 acetylation (p300) promotes DNA binding and is reversed by SIRT1 deacetylation.

SOCS and PIAS Negative Regulators

SOCS (suppressors of cytokine signalling) proteins (SOCS1–7, CIS) contain a central SH2 domain that binds receptor pTyr or JAK pTyr (SOCS1/3 KIR motif directly inhibits JAK2 Tyr1007 kinase domain; IC50 ~1 μM for SOCS3 inhibiting JAK2) and a C-terminal SOCS box (CUL5-RING E3 ligase adaptor) that recruits elongin BC → CRL5 → JAK/receptor K48-Ub degradation. SOCS1 is induced by IFN-γ→STAT1; SOCS3 by IL-6→STAT3 and by NF-κB. SOCS3 is the primary negative regulator of IL-6/STAT3 and also inhibits IRS-1 Tyr608 dephosphorylation (linking IL-6/JAK→SOCS3→insulin resistance). PIAS proteins (PIAS1–4) are SUMO E3 ligases that SUMOylate STAT1 Lys703 and STAT3 Lys87/Lys107→ nuclear export/transcriptional repression; PIAS also recruits HDAC to STAT-bound promoters.

Spirulina’s Mechanistic Actions

• NF-κB ↓ → IL-6/IL-1β ↓ → STAT3 Tyr705 ↓: PCB→IKKβ↓→NF-κB↓→IL-6 ↓ 30–50% (primary JAK2/STAT3 activator in inflammation)→JAK2 activation ↓→STAT3 Tyr705 ↓ 25–40% in LPS/IL-6-stimulated macrophages, liver, and adipose models.
• SIRT1 → STAT3 Lys685 deacetylation ↓: Elevated NAD&sup+;→SIRT1 ↑→STAT3 Lys685 deacetylation ↓→STAT3-DNA binding affinity ↓→STAT3 target genes (IL-6, IL-10, Bcl-2, cyclin D1, Snail) mRNA ↓ 20–35% in inflammatory contexts.
• Nrf2 → SOCS3 induction: Nrf2 activates SOCS3 (ARE-like element proposed at −600 bp of SOCS3 promoter); SOCS3 KIR domain inhibits JAK2 Tyr1007→STAT3 Tyr705 ↓ feedback; SOCS3 ↑ 15–25% in spirulina-treated IL-6-stimulated hepatocytes.
• STAT1 preservation (anti-pathogen): Spirulina does not suppress STAT1 Tyr701 (IFN-γ pathway) in standard anti-inflammatory doses; SOCS1 (STAT1 negative feedback) remains unchanged, preserving innate antiviral/antibacterial IFN signalling; selective STAT3-over-STAT1 suppression profile consistent with anti-inflammatory without immunosuppressive phenotype.
• STAT5 → EPO/growth signalling: AMPK modulation of mTORC1 normalises STAT5 Ser731 (mTORC1→STAT5 hyperphosphorylation in obesity promotes adipogenesis); STAT5 Tyr694 maintained for EPO→erythropoiesis support (consistent with spirulina’s anti-anaemia effects in B12/iron-replete context).

Clinical Correlates and Dosing

Animal models: spirulina 50–200 mg/kg reduces hepatic STAT3 Tyr705 25–40% in NAFLD/LPS models; IL-6 ↓ 30–50%; SOCS3 ↑ 15–25%. In cancer models (HCC, breast): STAT3-driven Bcl-2 and cyclin D1 ↓ 20–35% correlating with tumour growth inhibition. Human: CRP and IL-6 (STAT3 upstream inducers) ↓ 20–40% in RCTs; direct STAT3 measurements unavailable. JAK inhibitor (ruxolitinib, baricitinib) + spirulina: mechanistically additive STAT3 suppression; insufficient human data; theoretical co-benefit in autoimmune disease (RA, IBD).